Completed PHASE3 INTERVENTIONAL 2-arm NCT04632862

The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.

A Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase 3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus

Sponsor: Daewoong Pharmaceutical Co. LTD.

Conditions T2DM (Type 2 Diabetes Mellitus)

Interventions DWP16001

Updated 6 times since 2020 Last updated: Oct 23, 2022 Started: Nov 11, 2020 Primary completion: Nov 25, 2021 Completion: Nov 25, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on T2DM (Type 2 Diabetes Mellitus), this trial is completed. The trial is conducted by Daewoong Pharmaceutical Co. LTD. and has accumulated 6 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Nov 2022 — Jul 2024 [monthly]

Completed PHASE3

Status: Enrolling By Invitation → Completed
Jan 2021 — Nov 2022 [monthly]

Enrolling By Invitation PHASE3

▶ Show 1 earlier version

Dec 2020 — Jan 2021 [monthly]

Enrolling By Invitation PHASE3

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daewoong Pharmaceutical Co. LTD.

Data source: Daewoong Pharmaceutical Co. LTD.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea